Lenalidomide: A new therapy for multiple myeloma

AA Palumbo; JS Miguel; Pieter Sonneveld; P Moreau; J Drach; G Morgan; H Einsele

doi:10.1016/j.ctrv.2007.12.005

Lenalidomide: A new therapy for multiple myeloma

AA Palumbo, JS Miguel, Pieter Sonneveld, P Moreau, J Drach, G Morgan, H Einsele

Research output: Contribution to journal › Article › Academic › peer-review

29 Citations (Scopus)

Abstract

The last decade has seen rapid evolution in the management of multiple myetoma. Cytogenetic, molecular, and proteomic techniques have led to a better understanding of the pathophysiology and prognostic markers of this heterogeneous malignancy. New immunomodulatory drugs, such as lenalidomide, which interrupt myetoma growth and survival. pathways have entered into clinical usage. Combined with dexamethasone, oral lenalidomide has proved to be highly effective in patients whose disease has become resistant to conventional therapy. Currently, several. clinical trials are ongoing in order to define the optimal. use of this new agent and its combinations across the spectrum of patients with myetoma. Whether the ultimate outcome of future research wilt be a single-treatment solution for all patients, or whether treatments will become better-tailored to the individual (based on prognostic markers and preexisting co-morbidities) has yet to be determined. (c) 2007 Elsevier Ltd. All rights reserved.

Original language	Undefined/Unknown
Pages (from-to)	283-291
Number of pages	9
Journal	Cancer Treatment Reviews
Volume	34
Issue number	3
DOIs	https://doi.org/10.1016/j.ctrv.2007.12.005
Publication status	Published - 2008

Access to Document

10.1016/j.ctrv.2007.12.005

http://hdl.handle.net/1765/29643

Cite this

@article{3fc37193de53432ca0547aa97d9e258e,

title = "Lenalidomide: A new therapy for multiple myeloma",

abstract = "The last decade has seen rapid evolution in the management of multiple myetoma. Cytogenetic, molecular, and proteomic techniques have led to a better understanding of the pathophysiology and prognostic markers of this heterogeneous malignancy. New immunomodulatory drugs, such as lenalidomide, which interrupt myetoma growth and survival. pathways have entered into clinical usage. Combined with dexamethasone, oral lenalidomide has proved to be highly effective in patients whose disease has become resistant to conventional therapy. Currently, several. clinical trials are ongoing in order to define the optimal. use of this new agent and its combinations across the spectrum of patients with myetoma. Whether the ultimate outcome of future research wilt be a single-treatment solution for all patients, or whether treatments will become better-tailored to the individual (based on prognostic markers and preexisting co-morbidities) has yet to be determined. (c) 2007 Elsevier Ltd. All rights reserved.",

author = "AA Palumbo and JS Miguel and Pieter Sonneveld and P Moreau and J Drach and G Morgan and H Einsele",

year = "2008",

doi = "10.1016/j.ctrv.2007.12.005",

language = "Undefined/Unknown",

volume = "34",

pages = "283--291",

journal = "Cancer Treatment Reviews",

issn = "0305-7372",

number = "3",

}

TY - JOUR

T1 - Lenalidomide: A new therapy for multiple myeloma

AU - Palumbo, AA

AU - Miguel, JS

AU - Sonneveld, Pieter

AU - Moreau, P

AU - Drach, J

AU - Morgan, G

AU - Einsele, H

PY - 2008

Y1 - 2008

N2 - The last decade has seen rapid evolution in the management of multiple myetoma. Cytogenetic, molecular, and proteomic techniques have led to a better understanding of the pathophysiology and prognostic markers of this heterogeneous malignancy. New immunomodulatory drugs, such as lenalidomide, which interrupt myetoma growth and survival. pathways have entered into clinical usage. Combined with dexamethasone, oral lenalidomide has proved to be highly effective in patients whose disease has become resistant to conventional therapy. Currently, several. clinical trials are ongoing in order to define the optimal. use of this new agent and its combinations across the spectrum of patients with myetoma. Whether the ultimate outcome of future research wilt be a single-treatment solution for all patients, or whether treatments will become better-tailored to the individual (based on prognostic markers and preexisting co-morbidities) has yet to be determined. (c) 2007 Elsevier Ltd. All rights reserved.

AB - The last decade has seen rapid evolution in the management of multiple myetoma. Cytogenetic, molecular, and proteomic techniques have led to a better understanding of the pathophysiology and prognostic markers of this heterogeneous malignancy. New immunomodulatory drugs, such as lenalidomide, which interrupt myetoma growth and survival. pathways have entered into clinical usage. Combined with dexamethasone, oral lenalidomide has proved to be highly effective in patients whose disease has become resistant to conventional therapy. Currently, several. clinical trials are ongoing in order to define the optimal. use of this new agent and its combinations across the spectrum of patients with myetoma. Whether the ultimate outcome of future research wilt be a single-treatment solution for all patients, or whether treatments will become better-tailored to the individual (based on prognostic markers and preexisting co-morbidities) has yet to be determined. (c) 2007 Elsevier Ltd. All rights reserved.

U2 - 10.1016/j.ctrv.2007.12.005

DO - 10.1016/j.ctrv.2007.12.005

M3 - Article

VL - 34

SP - 283

EP - 291

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 3

ER -